Aims-To study the effects of ovarian hormone replacement therapy (HRT) on bone mineral density and disease activity in postmenopausal women with rheumatoid arthritis (RA). Method-A placebo controlled doubleblind study was carried out on 62 patients with RA, 22 on placebo and 40 on HRT (transdermal oestradiol patches twice weekly for 48 weeks plus norithisterone tablets when clinically indicated). Bone mineral density ofspine, hip and wrist was measured at 0 and 48 weeks and clinical and laboratory measures of general wellbeing and disease activity at 0, 12, 24 and 48 weeks. Results-Thirteen of 22 (59%/o) of placebo and 31 of 40 (78%) of the HRT group completed 48 weeks in the study. At entry, bone mineral density (BMD) values in the lumbar spine and femoral neck were similar to those in age and sex matched controls in both treatment groups, whereas at the distal radius, BMD was significantly reduced to approximately 50% of control values (both p < 0 001 from controls). In the HRT group, spine BMD increased significantly by a median of +0.94% at 48 weeks (p = 0.024), but did not change significantly in the placebo group. BMD at the femoral neck and distal radius did not change in either group. In the HRT group, there was significant improvement in well being as assessed by the Nottingham Health Care Profile (p < 0-01) and in the articular index (p < 0.05). There were no significant changes in ESR or CRP in either group. Conclusion-Transdermal HRT was weli tolerated, increased well being, reduced articular index and increased lumbar spine bone density over a one year period in postmenopausal women with RA.
and 31 of 40 (78%) of the HRT group completed 48 weeks in the study. At entry, bone mineral density (BMD) values in the lumbar spine and femoral neck were similar to those in age and sex matched controls in both treatment groups, whereas at the distal radius, BMD was significantly reduced to approximately 50% of control values (both p < 0 001 from controls). In the HRT group, spine BMD increased significantly by a median of +0.94% at 48 weeks (p = 0.024), but did not change significantly in the placebo group. BMD at the femoral neck and distal radius did not change in either group. In the HRT group, there was significant improvement in well being as assessed by the Nottingham Health Care Profile (p < 0-01) and in the articular index (p < 0.05). There were no significant changes in ESR or CRP in either group. Conclusion-Transdermal HRT was weli tolerated, increased well being, reduced articular index and increased lumbar spine bone density over a one year period in postmenopausal women with RA. Although no laboratory evidence was found of a disease modifying effect, the symptomatic benefits and improvements in bone density indicate that HRT may be a valuable adjunct to conventional antirheumatic therapy in RA.
(Ann Rheum Dis 1994; 53: 54-57)
Generalised osteoporosis with associated fractures of the spine and hip are a recognised complication of rheumatoid arthritis (RA).' 2 While the causes of systemic osteoporosis in RA are unclear, contributing factors include corticosteroid use, immobilisation, postmenopausal status, and the bone resorbing effects of pro-inflammatory cytokines.3 Whatever the underlying cause, postmenopausal women with RA represent a group at increased risk of osteoporotic fracture and this may contribute to the morbidity already experienced by these individuals.1 2 The role of sex hormones in protecting against osteoporosis are well established4 5 and it has been suggested that hormonal contraceptives and ovarian hormone replacement therapy (HRT), may protect against the development and progression of RA. [6] [7] [8] In the light of this, postmenopausal women with RA constitute a group who might be expected to derive particular benefit from HRT. Although short term oestrogen therapy has been shown to be of benefit in suppressing some aspects of disease activity in RA,9 the long-term effects of HRT in this situation are poorly documented. The aim of this study was to evaluate the effects of HRT on regional bone mass, disease activity and general well being in postmenopausal women with RA. Normal reference range for: CRP < 10 mg/I; ESR < 30 mm; haemoglobin 115-145 g/l.
Patients and methods
disease activity such as haemoglobin, platelet count, ESR or C-reactive protein in either the HRT or the placebo group, although the degree of inflammatory activity at baseline as judged by these variables was relatively low. The only significant between group differences were in well being (greater in the HRT group at week 48; -5.
-lo I . The therapeutic effects of sex hormones in RA have been little studied although a recent short term crossover trial of unopposed oestrogen suggested that this hormone may suppress some aspects of disease activity.9 In this study, we investigated the longer term effects of conventional HRT on disease activity and bone density in RA. We found that over a one year period, transdermal HRT resulted in a significant increase in median bone density of The loss of bone in placebo treated patients was greater in their study, however, (-2%) possibly due to the fact that their patients were studied within two to three years of the menopause compared with five to seven years in this study. Like Stevenson et al" and Sambrook et al,'2 who also studied the effects of sex hormones on bone density in RA, we found the protective effect of HRT on femoral neck density much less marked than in the lumbar spine. A recent study by van der Brink et al,'3 however, showed improvements in BMD at both sites. There are several potential explanations for these differences. Perhaps the most likely is that the femoral neck measurements largely reflect changes in cortical bone which remodels at a much slower rate than the trabecular bone of the vertebral bodies and hence may require longer periods of treatment to show changes, particularly in the light of the poorer precision of BMD measurements at the femoral neck. It has also been suggested that higher doses of oestrogen may be needed to prevent femoral bone loss in some cases."
The plasma oestradiol concentrations achieved in the present study (100-120 pmol/ 1) have previously been shown-on the basis of biochemical measurements-to be effective in suppressing bone turnover in normal postmenopausal women.'4 Some patients treated with HRT continued to lose bone despite this, however, (figure A-C) indicating that therapy may need to be tailored on an individual level on the basis of bone density measurements. Although the risk of osteoporotic fractures affecting both the hip and spine is increased by a factor of between 1-5-2-0 times in RA patients' 2 data has been presented to suggest that the pattern of bone loss in early RA is periarticular, rather than systemic in distribution.3 Our observations are consistent with this, as we found a marked reduction in bone density of the distal radius in RA patients, with BMD values in the spine and hip which were similar to those in an age and sex matched control population. While these data argue against a specific systemic osteoporosis in RA per se, it is probable that multiple factors such as steroid use, relative immobility, smoking and postmenopausal status may combine to increase the risk of bone loss and fracture in RA.' 2 The second aim of our study was to assess the tolerability of HRT in RA and study its effects on general well being and disease activity. An important finding was the excellent tolerability of HRT; only one patient on HRT withdrew from the study due to difficulties with resumption of menstrual bleeding and overall, 78% of the HRT group were still on therapy at two years compared with 59% in the placebo group. The high rate of compliance may have related to the symptomatic benefits which occurred in the HRT group. Particularly striking were the improvements in energy level, emotional level, and sleep patterns as assessed by the Nottingham Health Profile and the general well being score and articular index. We were, however, unable to demonstrate any specific antirheumatic effect as reflected by changes in ESR or C-reactive protein levels. Most of the patients studied were also taking disease modifying drugs, however, and as a result, had relatively low levels of ESR and CRP; it would be interesting to repeat the study in a group of patients with more evidence of inflammatory activity. The higher CRP level in the HRT group at week 24 is of doubtful significance and was probably related to random variation about the mean of the generally higher CRP levels observed in the HRT group.
In summary, we have found that HRT therapy in postmenopausal women with RA increased bone density in the lumbar spine, resulted in a significant improvement in general well being, but-in this group of patients at least-did not alter laboratory indices of disease activity. These symptomatic benefits, coupled with the protective effect on spinal bone density, however, indicate that HRT may be a useful adjunct to conventional therapy in the management of RA.
